The Management of Schizophrenia: Focus on Extended-release Quetiapine Fumarate

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2011 Oct 18

PMID 22003295

Citations 8

Authors

Joseph Peuskens

Affiliations

Soon will be listed here.

Abstract

Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity to further improve symptom control and long-term relapse prevention. Also, a number of factors, including tolerability and complex dosing regimens, can result in nonadherence to medication. Quetiapine is an atypical antipsychotic with proven efficacy and an established tolerability profile in schizophrenia. The once-daily extended-release formulation (quetiapine XR) offers a simplified dosing regimen and titration schedule. Short-term clinical studies have shown that quetiapine XR (400-800 mg/d) is efficacious in the acute treatment of schizophrenia, while a long-term study has shown that quetiapine XR was significantly more effective than placebo at preventing relapse. Furthermore, an investigation in which stable patients switched from the immediate-release formulation (quetiapine IR) to quetiapine XR showed that quetiapine XR is generally well tolerated and has no loss of efficacy compared with quetiapine IR. In patients who experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching to quetiapine XR significantly improved efficacy compared with the previous treatment. In conclusion, quetiapine XR is an effective and generally well tolerated treatment for schizophrenia. Furthermore, once-daily dosing may improve patient adherence, which may impact positively on patient outcomes.

Citing Articles

The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?.

Lippi M, Fanelli G, Fabbri C, De Ronchi D, Serretti A Int Clin Psychopharmacol. 2022; 37(6):263-275.

PMID: 35815937 PMC: 9521590. DOI: 10.1097/YIC.0000000000000417.

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder.

Seetasith A, Greene M, Hartry A, Burudpakdee C Clinicoecon Outcomes Res. 2019; 11:741-755.

PMID: 31824181 PMC: 6900467. DOI: 10.2147/CEOR.S220007.

Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles.

Huang X, Zhang S, Ma Y, Yang H, He C, Tian R Drug Des Devel Ther. 2019; 13:255-264.

PMID: 30643391 PMC: 6319427. DOI: 10.2147/DDDT.S182965.

Schizophrenia: synthetic strategies and recent advances in drug design.

Azmanova M, Pitto-Barry A, Barry N Medchemcomm. 2018; 9(5):759-782.

PMID: 30108966 PMC: 6072500. DOI: 10.1039/c7md00448f.

Drug-induced gastrointestinal disorders.

Philpott H, Nandurkar S, Lubel J, Gibson P Frontline Gastroenterol. 2017; 5(1):49-57.

PMID: 28839751 PMC: 5369702. DOI: 10.1136/flgastro-2013-100316.

References

Tandon R, Jibson M . Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002; 14(2):123-9. DOI: 10.1023/a:1016811222688. View

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D . Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2009; 121(1-2):106-15. DOI: 10.1016/j.jad.2009.10.007. View

Weiden P, Preskorn S, Fahnestock P, Carpenter D, Ross R, Docherty J . Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. J Clin Psychiatry. 2007; 68 Suppl 7:1-48. View

Byerly M, Nakonezny P, Lescouflair E . Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007; 30(3):437-52. DOI: 10.1016/j.psc.2007.04.002. View

Ascher-Svanum H, Faries D, Zhu B, Ernst F, Swartz M, Swanson J . Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 67(3):453-60. DOI: 10.4088/jcp.v67n0317. View

Tandon R, Marcus R, Stock E, Riera L, Kostic D, Pans M . A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res. 2006; 84(1):77-89. DOI: 10.1016/j.schres.2005.12.857. View

Figueroa C, Brecher M, Hamer-Maansson J, Winter H . Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 33(2):199-204. DOI: 10.1016/j.pnpbp.2008.09.026. View

Meulien D, Huizar K, Brecher M . Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2010; 25(2):103-15. DOI: 10.1002/hup.1091. View

Perkins D, Gu H, Weiden P, McEvoy J, Hamer R, Lieberman J . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008; 69(1):106-13. DOI: 10.4088/jcp.v69n0114. View

10.

McElroy S, Weisler R, Chang W, Olausson B, Paulsson B, Brecher M . A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 71(2):163-74. DOI: 10.4088/JCP.08m04942gre. View

11.

Saini S, Schoenfeld P, Kaulback K, Dubinsky M . Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009; 15(6):e22-33. View

12.

Nemeroff C, Kinkead B, Goldstein J . Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2003; 63 Suppl 13:5-11. View

13.

Leucht S, Kissling W, Davis J . Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychol Med. 2009; 39(10):1591-602. DOI: 10.1017/S0033291709005455. View

14.

Kikkert M, Schene A, Koeter M, Robson D, Born A, Helm H . Medication adherence in schizophrenia: exploring patients', carers' and professionals' views. Schizophr Bull. 2006; 32(4):786-94. PMC: 2632275. DOI: 10.1093/schbul/sbl011. View

15.

Jensen N, Rodriguiz R, Caron M, Wetsel W, Rothman R, Roth B . N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2007; 33(10):2303-12. DOI: 10.1038/sj.npp.1301646. View

16.

El-Khalili N, Joyce M, Atkinson S, Buynak R, Datto C, Lindgren P . Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled.... Int J Neuropsychopharmacol. 2010; 13(7):917-32. DOI: 10.1017/S1461145710000015. View

17.

Valenstein M, Ganoczy D, McCarthy J, Kim H, Lee T, Blow F . Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67(10):1542-50. DOI: 10.4088/jcp.v67n1008. View

18.

Katzman M, Brawman-Mintzer O, Reyes E, Olausson B, Liu S, Eriksson H . Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2010; 26(1):11-24. DOI: 10.1097/YIC.0b013e32833e34d9. View

19.

Jonsdottir H, Friis S, Horne R, Pettersen K, Reikvam A, Andreassen O . Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2008; 119(1):78-84. DOI: 10.1111/j.1600-0447.2008.01279.x. View

20.

Young A, McElroy S, Bauer M, Philips N, Chang W, Olausson B . A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010; 71(2):150-62. DOI: 10.4088/JCP.08m04995gre. View